Notice of Refund | Feb 1, 2018 | PAPER | BOARD |
Petitioner's Request for Refund | Jan 25, 2018 | PAPER | PETITIONER |
Trial Instituted Document | Jan 23, 2018 | PAPER | BOARD |
Patent Owner's Preliminary Response | Nov 3, 2017 | PAPER | PATENT OWNER |
Notice of Accepting Petition Corrections | Aug 17, 2017 | PAPER | BOARD |
Response to Notice of Filing Date Accorded to Petition | Aug 9, 2017 | PAPER | PETITIONER |
Citron et al., Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer | Aug 9, 2017 | EXHIBIT | PETITIONER |
Notice of Accord Filing Date | Aug 7, 2017 | PAPER | BOARD |
Patent Owner's Mandatory Notices | Jul 20, 2017 | PAPER | PATENT OWNER |
Genentech's Power of Attorney | Jul 20, 2017 | PAPER | PATENT OWNER |
PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 8,591,897 UNDER 35 U.S.C. 311 AND 37 C.F.R. 42.100 | Jun 30, 2017 | PAPER | PETITIONER |
PFIZER, INCS POWER OF ATTORNEY IN AN INTER PARTES REVIEW | Jun 30, 2017 | PAPER | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 1 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 2 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 3 | Jun 30, 2017 | EXHIBIT | PETITIONER |
U.S Patent No. 8,591,897 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 4 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 8 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 5 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 6 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 7 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Declaration of Allan Lipton, M.D. | Jun 30, 2017 | EXHIBIT | PETITIONER |
ClinicalTrials.gov, Clinical Trial: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (archived March 7, 2004) | Jun 30, 2017 | EXHIBIT | PETITIONER |
1103A - Dr. Allan Lipton, Curriculum Vitae and Materials Considered | Jun 30, 2017 | EXHIBIT | PETITIONER |
Tan and Swain, Ongoing Adjuvant Trials With Trastuzumab in Breast Cancer, 30(5, Suppl. 16) SEMINARS IN ONCOL. (2003) | Jun 30, 2017 | EXHIBIT | PETITIONER |
ClinicalTrials.gov, Background (Accessed June 10, 2017) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Van Pelt et al., Neoadjuvant Trastuzumab and Docetaxel in Patients with Breast Cancer Preliminary Results, 4(5) CLIN. BREAST CANCER (2003) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Sledge et al., Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer (E2198), 69(3) BREAST CANCER RESEARCH AND TREATMENT (Abstracts - General Sessions 4) 209 (2001) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Gradishar et al., Progress in Systemic Adjuvant Therapy of Early-stage Breast Cancer, 8(4) INTL. J.CLIN. ONCOL. 239-47 (2003) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Herceptin (Trastuzumab) Product Label (Sept. 1998) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Devita et al., Principles And Practice Of Oncology, Vol. 2 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Slamon et al., Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2, 344(11) N. Engl. J. Med. (2001) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Piccart-Gebhart et al., Herceptin: The Future in Adjuvant Breast Cancer Therapy, 12(4) Anti-Cancer Drugs Suppl. S27S33 (2001) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Perez et al., Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients with Breast Cancer in the North Center Cancer Treatment Group N9831 Intergroup Adjuvant Trial, 22(18) J. Clin. Oncol. (2004) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Citron et al., Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Devita et al., Principles And Practice Of Oncology, Vol. 1 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Thomas et al., New Paradigms in Adjuvant Systemic Therapy of Breast Cancer, 10(1) Endocrine-Related Cancer (2003) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Devita et al., Principles And Practice Of Oncology, Vol. 3 | Jun 30, 2017 | EXHIBIT | PETITIONER |
ClinicalTrials.gov, History, Policies, and Laws (Accessed June 11, 2017) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Pegram et al., Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant 16(8) J. Clin. Oncol. (1998) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Pegram et al., Phase II Study of Intravenous Recombinant Humanized Anti-p185 HER-2 Monoclonal, 14 PROGRAM/Proc. Am. Socy Clin. Oncol., 106 (Abstract 124) (1995) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Baselga et al., Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2neu-Overexpressing Metastatic Breast Cancer, 14(3) J.CLIN. ONCOL.(1996) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Herceptin (Trastuzumab) Product Label (2017) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Romond et al., Trastuzumab plus Adjuvant Chemotherapy for Operable HER2Positive Breast Cancer, 353 N. Engl. J. Med. ( 2005) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Perez et al., Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2Positive Breast Cancerint: Jo Analysis of Data from NCCTG N9831 and NSABP B-31, 29(24) J. Clin. Oncol. ( 2011) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Harlow et al., Using Antibodies, A Laboratory Manual (Cold Spring Harbor Press), Ch. 1 and 11 (1999), Vol. 1 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epiderman Growth Factor or HER2neu Gene Product, 50(5) Cancer Research, (1990) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Tan 03 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Van Pelt 03 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Harlow et al., Using Antibodies, A Laboratory Manual (Cold Spring Harbor Press), Ch. 1 and 11 (1999), Vol. 2 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Vogel et al., Clinical Experience with Trastuzumab (Herceptin), 9(6) The Breast Journal (2003) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Buzdar et al., Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: 23(18) J. Clin. Oncol.3676-85 (2005) | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Perez 04 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Citron 03 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Devita 01 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Slamon 01 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Fendly 90 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Declaration of Amanda Hollis | Jun 30, 2017 | EXHIBIT | PETITIONER |
Declaration of Christopher Lowden | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Pegram 98 | Jun 30, 2017 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 8,591,897, Vol. 9 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Baselga 96 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Romond 05 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Harlow 99 | Jun 30, 2017 | EXHIBIT | PETITIONER |
Library of Congress Copyright Record for Buzdar 05 | Jun 30, 2017 | EXHIBIT | PETITIONER |